New trispecific antibody for the treatment of various subtypes of B-cell lymphoma

B-cell lymphomas are a group of cancers that arise from a subgroup of white blood cells known as B lymphocytes. They are part of the immune system and play a role in defending the body against pathogens, for example. When these cells become malignant, various types of lymphoma can develop. These include large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Standard treatment usually consists of immunochemotherapy, which also incorporates new drugs that specifically target structures on the malignant cells and thus act with great precision. New drugs are designed to combat lymphoma cells with ever-greater effectiveness and precision. AZD5492 is a novel, triple-acting antibody (trispecific T-cell engager). It simultaneously binds to three surface proteins on B cells and T cells—another subtype of immune cells: CD20—a protein on the surface of B cells, including malignant cells; CD8—a marker on cytotoxic T cells (CD8-positive T cells) that can kill cancer cells; and the T-cell receptor (TCR)—a molecule that activates T cells to specifically target cancer cells. By binding simultaneously to three target structures, AZD5492 brings T cells into close proximity to the cancer cells, enabling the targeted destruction of tumor cells. Unlike previous bispecific antibodies, AZD5492 selectively targets CD8-positive T cells. This could reduce the risk of side effects such as cytokine release syndrome (CRS) and neurological complications.

The goal of the TITANium study is to investigate the optimal dosage and efficacy of the trispecific antibody AZD5492 in patients with advanced B-cell lymphoma whose disease persists or has recurred after at least two prior treatments. The study is open-label, meaning that both patients and physicians know that the drug is being administered. It is given as monotherapy. The study consists of separate phases, each of which evaluates the safety, tolerability, and efficacy of AZD5492. The drug is administered via subcutaneous injection. Follow-up will continue for up to 2 years after the last dose is administered.

Men and women aged 18 and older who have one of the following B-cell lymphomas are eligible to participate: large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, small-cell lymphoma, and who have undergone at least two previous unsuccessful treatments. The B-cell lymphoma must be histologically confirmed, and the cancer cells must express the surface protein CD20. There must be no involvement of the central nervous system.